Kayne Anderson Rudnick Investment Management LLC lifted its position in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 4.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,189 shares of the medical instruments supplier’s stock after purchasing an additional 3,001 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC owned 1.87% of Mesa Laboratories worth $10,059,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of MLAB. Strs Ohio raised its position in Mesa Laboratories by 5.6% in the 2nd quarter. Strs Ohio now owns 1,900 shares of the medical instruments supplier’s stock valued at $272,000 after buying an additional 100 shares during the last quarter. Eqis Capital Management Inc. raised its position in Mesa Laboratories by 5.6% in the 2nd quarter. Eqis Capital Management Inc. now owns 5,188 shares of the medical instruments supplier’s stock valued at $744,000 after buying an additional 273 shares during the last quarter. Swiss National Bank raised its position in Mesa Laboratories by 9.6% in the 2nd quarter. Swiss National Bank now owns 5,702 shares of the medical instruments supplier’s stock valued at $817,000 after buying an additional 500 shares during the last quarter. Spark Investment Management LLC purchased a new stake in Mesa Laboratories in the 2nd quarter valued at $300,000. Finally, Bessemer Group Inc. raised its position in Mesa Laboratories by 716.7% in the 2nd quarter. Bessemer Group Inc. now owns 4,900 shares of the medical instruments supplier’s stock valued at $702,000 after buying an additional 4,300 shares during the last quarter. 67.20% of the stock is currently owned by institutional investors.

Mesa Laboratories, Inc. (MLAB) opened at 135.67 on Thursday. The firm has a 50-day moving average price of $138.15 and a 200-day moving average price of $137.55. Mesa Laboratories, Inc. has a 52 week low of $107.98 and a 52 week high of $169.80. The company has a market cap of $509.85 million, a P/E ratio of 48.77 and a beta of 0.47.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings results on Monday, July 31st. The medical instruments supplier reported $0.39 EPS for the quarter, missing analysts’ consensus estimates of $0.56 by $0.17. Mesa Laboratories had a net margin of 11.31% and a return on equity of 16.58%. The firm had revenue of $22.67 million for the quarter, compared to the consensus estimate of $22.90 million. Equities research analysts anticipate that Mesa Laboratories, Inc. will post $2.72 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Thursday, August 31st will be paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.47%. The ex-dividend date is Tuesday, August 29th. Mesa Laboratories’s payout ratio is presently 22.94%.

A number of equities research analysts recently commented on the company. TheStreet lowered Mesa Laboratories from a “b” rating to a “c+” rating in a research report on Monday, July 31st. Zacks Investment Research raised Mesa Laboratories from a “hold” rating to a “buy” rating and set a $159.00 price target for the company in a research report on Tuesday, June 13th. Finally, BidaskClub lowered Mesa Laboratories from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th.

ILLEGAL ACTIVITY WARNING: “Kayne Anderson Rudnick Investment Management LLC Raises Stake in Mesa Laboratories, Inc. (MLAB)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/07/kayne-anderson-rudnick-investment-management-llc-raises-stake-in-mesa-laboratories-inc-mlab.html.

In related news, insider Glenn E. Adriance sold 4,000 shares of the stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $148.98, for a total transaction of $595,920.00. Following the completion of the transaction, the insider now directly owns 10,000 shares of the company’s stock, valued at $1,489,800. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director H Stuart Campbell sold 2,000 shares of the stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $143.37, for a total value of $286,740.00. Following the transaction, the director now directly owns 49,976 shares of the company’s stock, valued at $7,165,059.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,760 shares of company stock valued at $3,469,708. 17.00% of the stock is owned by corporate insiders.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Want to see what other hedge funds are holding MLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mesa Laboratories, Inc. (NASDAQ:MLAB).

Institutional Ownership by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Stock Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related stocks with our FREE daily email newsletter.